Laura Huppert, MD, is an assistant professor of medicine in the Department of Medicine at the University of California, San Francisco School of Medicine

Laura Huppert, MD discusses LBA20 – primary results from ASCENT-03: a randomized phase 3 study of Sacituzumab Govitecan (SG) vs chemotherapy (Chemo) in patients (Pts) with previously untreated Advanced Triple-Negative Breast Cancer (TNBC) who are unable to receive PD-(L)1 inhibitors (PD-[L]1i).

LBA20 – Primary Results from ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (Pts) with Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)1 Inhibitors (PD-[L]1i)

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Laura Huppert, MD discusses LBA20 – primary results from ASCENT-03: a randomized phase 3 study of Sacituzumab Govitecan (SG) vs chemotherapy (Chemo) in patients (Pts) with previously untreated Advanced Triple-Negative Breast Cancer (TNBC) who are unable to receive PD-(L)1 inhibitors (PD-[L]1i)

Primary Results from ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan vs Chemotherapy in Patients with Previously Untreated Advanced Triple-Negative Breast Cancer Who Are Unable to Receive PD-(L)1 Inhibitors